Cameron Reynolds is recorded as Board Member at Volitionrx Ltd (VNRX) since January 1, 2011 and CEO at Volitionrx Ltd (VNRX). The newest filing on record that lists Cameron Reynolds as Board Member at Volitionrx Ltd (VNRX) is dated April 29, 2021. Volitionrx Ltd reported in an 8-K filed July 3, 2024 a re-election or new board role (member of the Board of Directors) for Cameron Reynolds, on the board since at least 2011, effective July 2, 2024. Volitionrx Ltd reported in an 8-K filed June 30, 2023 a re-election or new board role (member to the Board of Directors) for Cameron Reynolds, on the board since at least 2011, effective June 28, 2023. The proxy statement of Volitionrx Ltd reports total compensation of $517,691 for Cameron Reynolds in fiscal 2019, including a base salary of $390,592. Disclosed compensation is on record for 2 fiscal years. Cameron Reynolds has spoken on 24 earnings calls across 1 company, most recently for Volitionrx Ltd on November 13, 2026. Volitionrx Ltd is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Volitionrx Ltd includes Dr. Jasmine Kway (CEO and Board Member), Dr. Martin Faulkes (Chairman and Board Member), Guy Innes (Chairman and Board Member) and 7 others.
“The stockholders elected six members to the Board of Directors to hold office until the 2025 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation or removal.”
Volitionrx Ltd Form 8-K, filed July 3, 2024
· Read the filing
“The stockholders elected eight members to the Board of Directors to hold office until the 2024 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation or removal.”
Volitionrx Ltd Form 8-K, filed June 30, 2023
· Read the filing
Cameron Reynolds on recent calls
“As always, we very much appreciate your time, given the busy earnings season. I'll begin just by saying I have a croaking throat today, so I will take it nice and slow, and I apologize for my voice.”
“As always, we very much appreciate your time, given the busy earnings season. We have made strong progress across all our product pillars so far in 2026. So taking each in turn, first, starting with NuQ-Nets.”
“As always, we very much appreciate your time given the busy earnings season. The first quarter call always comes hot on the heels of the K. so I will try and be brief today.”
“Thanks, Lou, and thank you, everyone, for joining Volition's Third Quarter 2025 Earnings Call today. We very much appreciate your time given the busy earnings season.”
“2025 is a pivotal year for Volition as we focus on commercializing our groundbreaking Nu.Q platform in the human diagnostic market. As reported previously, we are in confidential discussions with over 10 companies, and I'm very happy with progress on many fronts.”
